New vaccine aims to shield against 24 pneumonia strains
NCT ID NCT07543198
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new 24-valent pneumococcal conjugate vaccine (PCV24) in 385 healthy adults aged 18 and older. The goal was to check its safety and how well it triggers an immune response compared to an existing vaccine. Participants received one dose of either a low, middle, or high dose of PCV24 or a standard vaccine, and were monitored for side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
24-valent pneumococcal conjugate vaccine (PCV24)
What this could lead to
If successful, this vaccine could protect against more types of pneumococcal bacteria than current vaccines, reducing pneumonia and related infections.
What could go wrong
This is an early-phase trial with only 385 participants, so results may not apply to everyone. The vaccine may cause side effects or not work as well as expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shaanxi Provincial Center for Disease Control and Prevention
Xi'an, Shaanxi, China